Drug Trial Radar · NCT06290141
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Aug 21, 2024
Primary completion
Jul 9, 2027
Study completion Jan 12, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
riliprubartDrug
Pharmaceutical form: Solution Route of administration: IV solution
PlaceboDrug
Pharmaceutical form: Solution Route of administration: IV solution
riliprubartDrug
Pharmaceutical form: Solution Route of administration: SC solution
PlaceboDrug
Pharmaceutical form: Solution Route of administration: SC solution
IVIgDrug
Pharmaceutical form: Concentrate for solution for infusion (or any other formulation approved locally) Route of administration: IV solution
PlaceboDrug
Pharmaceutical form: Placebo to match intravenous immunoglobulin IVIg for IV infusio Route of administration: IV solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants experiencing a responseTime frame: Baseline to week 24
- Percentage of participants randomized to riliprubart who responded during part A and had a lasting response during the open-label treatment extension periodTime frame: Baseline to week 48
Locations
138 sites in 24 countries. Site status is shown where the registry gives one.
Alabama Neurology Associates- Site Number : 8400019
Homewood, Alabama · Recruiting
HonorHealth Bob Bove Neuroscience Institute - Site Number : 8400014
Scottsdale, Arizona · Recruiting
University Of Southern California- Site Number : 8400002
Los Angeles, California · Recruiting
University of California Irvine - Manchester Pavilion- Site Number : 8400007
Orange, California · Recruiting
IMMUNOe International Research Centers - Centennial- Site Number : 8400049
Centennial, Colorado · Recruiting
Yale University School Of Medicine Department Of Neurology- Site Number : 8400018
Fairfield, Connecticut · Recruiting
DM Clinical Research - Bradenton- Site Number : 8400044
Bradenton, Florida · Recruiting
Research by Design, LLC- Site Number : 8400053
Miami Lakes, Florida · Recruiting
AdventHealth Orlando- Site Number : 8400006
Orlando, Florida · Recruiting
Endeavor Health - NorthShore Kellogg Cancer Center - Glenbrook- Site Number : 8400024
Glenview, Illinois · Recruiting
University of Kansas Medical Center- Site Number : 8400010
Kansas City, Kansas · Recruiting
Ochsner Medical Center - Jefferson Highway- Site Number : 8400030
New Orleans, Louisiana · Recruiting
Wilmer Instit John Hopkins Hosp Univ Sch Medicine- Site Number : 8400015
Baltimore, Maryland · Recruiting
Massachusetts General Hospital-Genetics- Site Number : 8400009
Boston, Massachusetts · Recruiting
Henry Ford Hospital- Site Number : 8400025
Detroit, Michigan · Recruiting
Michigan State University- Site Number : 8400038
East Lansing, Michigan · Recruiting
Washington University School of Medicine- Site Number : 8400037
St Louis, Missouri · Recruiting
Profound Research- Site Number : 8400052
Las Vegas, Nevada · Recruiting
Dent Neurologic Institute - Amherst- Site Number : 8400039
Amherst, New York · Recruiting
Northwell Health Physician Partners Dermatology at Lake Success- Site Number : 8400051
Lake Success, New York · Recruiting
Hospital for Special Surgery - Site Number : 8400041
New York, New York · Recruiting
Columbia University Irving Medical Center- Site Number : 8400003
New York, New York · Recruiting
Raleigh Neurology Associates- Site Number : 8400043
Raleigh, North Carolina · Recruiting
University of Cincinnati Medical Center- Site Number : 8400020
Cincinnati, Ohio · Recruiting
University Hospitals Cleveland Medical Center- Site Number : 8400033
Cleveland, Ohio · Recruiting
Penn State Health Milton South Hershey Medical Center- Site Number : 8400042
Hershey, Pennsylvania · Recruiting
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400022
Philadelphia, Pennsylvania · Recruiting
Austin Neuromuscular Center- Site Number : 8400040
Austin, Texas · Recruiting
Gadolin Research - Beaumont- Site Number : 8400047
Beaumont, Texas · Recruiting
Uthealth - The University Of Texas Health Sciences Center At Houston- Site Number : 8400050
Houston, Texas · Recruiting
University of Vermont Medical Center- Site Number : 8400012
Burlington, Vermont · Completed
University of Virginia- Site Number : 8400023
Charlottesville, Virginia · Recruiting
Investigational Site Number : 0320001
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320002
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0320003
Buenos Aires, Argentina · Recruiting
Investigational Site Number : 0560002
Ghent, Belgium · Completed
Investigational Site Number : 0560001
Leuven, Belgium · Recruiting
PSEG Centro de Pesquisa Clínica- Site Number : 0760009
São Paulo, Brazil · Recruiting
L2IP - Instituto de Pesquisas Clínicas- Site Number : 0760006
Brasília, Federal District, Brazil · Recruiting
Fundação Universidade Federal de Mato Grosso do Sul- Site Number : 0760020
Campo Grande, Mato Grosso do Sul, Brazil · Recruiting
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.